(Q33926126)

English

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

0 references

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials (English)

1 reference

Europe PubMed Central

30 July 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wen-Cong Li

1

1 reference

Europe PubMed Central

30 July 2017

Mao-Rong Wang

2

1 reference

Europe PubMed Central

30 July 2017

Ling-Bo Kong

3

1 reference

Europe PubMed Central

30 July 2017

Wei-Guang Ren

4

1 reference

Europe PubMed Central

30 July 2017

Yu-Guo Zhang

5

1 reference

Europe PubMed Central

30 July 2017

Yue-Min Nan

6

1 reference

Europe PubMed Central

30 July 2017

publication date

9 June 2011

1 reference

Europe PubMed Central

30 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

30 July 2017

11

1 reference

Europe PubMed Central

30 July 2017

165

1 reference

Europe PubMed Central

30 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2334-11-165

0 references

Hepatitis B: diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Chronic hepatitis B: update 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Hepatitis B: reflections on the current approach to antiviral therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

5 July 2018

Current treatment indications and strategies in chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128052

29 October 2018

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-165

21 January 2018

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis B: update of recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Pegylated interferon alpha 2a in treating chronic hepatitis B patients]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21651820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-11-165

1 reference

Europe PubMed Central

30 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33926126&oldid=1644802027"